5 Best Genomics Stocks To Buy Now

In this piece, we will take a look at the five best genomics stocks to buy now. If you want to learn more about the revolutionary genomics industry, then check out 12 Best Genomics Stocks To Buy Now.

5. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of Hedge Fund Investors In Q3 2023: 27

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a gene editing company developing treatments for cancer and immune system diseases. Its shares are rated Strong Buy on average and analysts have set an average share price target of $76.

By the end of Q3 2023, 27 out of the 910 hedge funds part of Insider Monkey’s research had invested in Intellia Therapeutics, Inc. (NASDAQ:NTLA). Catherine D. Wood’s ARK Investment Management was the largest shareholder through its $314 million stake.

4. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Number of Hedge Fund Investors In Q3 2023: 29

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is an American firm that develops RNA based therapies. The firm was out with some great news in November 2023 when it shared that a trial of its sub surface skin swelling disease reduced attack rates by a strong 96%.

Insider Monkey scoured through 910 hedge funds for their investments during 2023’s September quarter to discover that 29 had bought the firm’s shares. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)’s biggest hedge fund investor is Mark Lampert’s Biotechnology Value Fund / BVF Inc as it owns $181 million worth of shares.

3. Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Number of Hedge Fund Investors In Q3 2023: 31

Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a backend genomics company that provides products such as sequencing and temple preparation kits. It expanded its gene sequencing platform in November 2023 when it added two new partners.

As of September 2023 end, 31 out of the 910 hedge funds profiled by Insider Monkey were Pacific Biosciences of California, Inc. (NASDAQ:PACB)’s investors. Out of these, the largest shareholder is Catherine D. Wood’s ARK Investment Management due to its $249 million stake.

2. Illumina, Inc. (NASDAQ:ILMN)

Number of Hedge Fund Investors In Q3 2023: 40

Illumina, Inc. (NASDAQ:ILMN) is another scientific products company that caters to the needs of the genomics industry. The firm has beaten analyst EPS estimates in all four of its latest quarters and the shares are rated Buy on average.

By the end of this year’s third quarter, 40 out of the 910 hedge funds covered by Insider Monkey’s research had invested in the company. Illumina, Inc. (NASDAQ:ILMN)’s biggest investor among these is Guardian Capital’s GuardCap Asset Management as it owns 2 million shares that are worth $286 million.

1. Natera, Inc. (NASDAQ:NTRA)

Number of Hedge Fund Investors In Q3 2023: 49

Natera, Inc. (NASDAQ:NTRA) is a diagnostics company that enables people to discover genetic abnormalities. Its shares are also rated Strong Buy on average and analysts have set an average share price target of $71.87.

49 out of the 910 hedge funds profiled by Insider Monkey had bought Natera, Inc. (NASDAQ:NTRA)’s shares during Q3 2023. Robert Pohly’s Samlyn Capital was the largest hedge fund shareholder as it owned $194 million worth of shares.

Disclosure: None. You can also take a look at 12 Most Promising Stocks to Buy According to Hedge Funds and Billionaire Louis Bacon’s 10 Stock Picks with Huge Upside Potential.

Follow Insider Monkey on Twitter